Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by Windmill Hill Asset Management Ltd

Windmill Hill Asset Management Ltd grew its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 299.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 104,373 shares of the company’s stock after acquiring an additional 78,252 shares during the quarter. Neumora Therapeutics comprises approximately 1.1% of Windmill Hill Asset Management Ltd’s portfolio, making the stock its 12th biggest position. Windmill Hill Asset Management Ltd’s holdings in Neumora Therapeutics were worth $1,106,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. The Manufacturers Life Insurance Company grew its holdings in shares of Neumora Therapeutics by 79.5% during the second quarter. The Manufacturers Life Insurance Company now owns 111,828 shares of the company’s stock worth $1,099,000 after buying an additional 49,527 shares during the last quarter. Handelsbanken Fonder AB raised its stake in shares of Neumora Therapeutics by 35.0% during the third quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company’s stock worth $351,000 after purchasing an additional 6,900 shares during the last quarter. Clarius Group LLC acquired a new stake in shares of Neumora Therapeutics during the third quarter worth $224,000. Ballentine Partners LLC purchased a new position in Neumora Therapeutics in the 3rd quarter valued at $178,000. Finally, Auour Investments LLC acquired a new position in Neumora Therapeutics in the 3rd quarter valued at $3,302,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on NMRA shares. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research note on Thursday, January 2nd. Royal Bank of Canada downgraded shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $29.00 to $4.00 in a research report on Thursday, January 2nd. JPMorgan Chase & Co. cut Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Bank of America reduced their price target on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a report on Monday, January 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Neumora Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Neumora Therapeutics Trading Up 0.5 %

NMRA opened at $1.95 on Friday. The business’s fifty day moving average is $6.30 and its two-hundred day moving average is $10.20. Neumora Therapeutics, Inc. has a one year low of $1.81 and a one year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period last year, the firm earned ($1.14) EPS. Analysts forecast that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.